Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: A randomized, double-blind, placebo-controlled, efficacy trial

Journal of Clinical Psychiatry

Volumn 73, Issue 3, 2012, Pages 353-357

  Mischoulon, David ^a   Witte, Janet ^a   Levy, Michael ^a   Papakostas, George I ^a   Pet, L Russell ^a   Hsieh, Wen Hua ^a,b   Pencina, Michael J ^b   Ward, Sean ^a   Pollack, Mark H ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

9 ITEM PATIENT HEALTH QUESTIONNAIRE; ABNORMAL DREAMING; ADULT; AGED; AKATHISIA; AMNESIA; ANXIETY; ARTICLE; BRONCHITIS; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENITAL HERPES; HEADACHE; HERPES ZOSTER; HUMAN; HYPOMANIA; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOM DISTRESS SCALE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREMOR; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA;

EID: 84859152243     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06541     Document Type: Article

References (16)

1. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127. doi:10.159/069738 PubMed (Pubitemid 36469860)
2. Trivedi MH, Fava M, Wisniewski SR, et al; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252. doi:10.1056/NEJMoa052964 PubMed
3. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991. doi:10.176/api.ajp.209.09030312 PubMed
4. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. doi:10.408/JCP.v68n0604 PubMed (Pubitemid 47015482)
5. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165. doi:10.1097/JCP.0b013e3181674f9 PubMed (Pubitemid 351417120)
6. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009; 14(4):197-206. PubMed
7. Fava M, Mischoulon D, Iosifescu DV, et al. Double-Blind, Placebo- Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Depressed Outpatients with Inadequate Response to Prior ADT (ADAPT-A Study). Presented at the annual meeting of the 48th American College of Neuropsychopharmacology; December 6-10, 2009; Hollywood, FL; and at the 50th annual meeting of the New Clinical Drug Evaluation Unit; June 14-17, 2010; Boca Raton, FL.
8. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relevance for drug development. CNS Neurosci Ther. 2008;14(1):2-9. doi:10.1/j.175-5949. 208.038.x PubMed
9. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325. doi:10.1/j.175-5949.209.0102.x PubMed
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
12. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. doi:10.1016/S06-323(02)0186-8 PubMed (Pubitemid 37289444)
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institutes of Health; 1976.
14. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.201.01609606.x PubMed (Pubitemid 32823891)
15. Kellner R. A symptom questionnaire. J Clin Psychiatry. 1987;48(7): 268-274. PubMed (Pubitemid 17108403)
16. Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology. 2010;62(1):36-42.